Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -1.47%77 3-Year FCF Growth Rate is 7.50% as of Mar. 2026, which is at its 10-year median of 7.50. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 585 Medical Devices & Instruments companies, Coloplast AS ranks worse than 60.17% on this metric.
During the past 12 months, Coloplast AS's average Free Cash Flow per Share Growth Rate was 21.40% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 7.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -4.80% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 1.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Coloplast AS was 44.10% per year. The lowest was -26.00% per year. And the median was 7.50% per year.
Coloplast AS (OTCPK:CLPBY) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Coloplast AS 3-Year FCF Growth Rate Related Terms
CLPBY vs ISRG, BDX, MDLN: 3-Year FCF Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Coloplast AS's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Coloplast AS (CLPBY) has a 3-Year FCF Growth Rate of 7.50% as of Mar. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Coloplast AS and its competitors. This is near median its historical median of 7.50. According to the industry distribution chart, Coloplast AS ranks #352 out of 585 companies in the Medical Devices & Instruments industry, placing it in the top 60.2%.
Is Coloplast AS's 3-Year FCF Growth Rate too high?
Coloplast AS's current 3-Year FCF Growth Rate of 7.50% is near median its 10-year median of 7.50. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 17.90. Coloplast AS's value of 7.50% is 58.1% below this industry median. Based on the distribution chart, Coloplast AS ranks #352 out of 585 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's 3-Year FCF Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #352 out of 585 companies for 3-Year FCF Growth Rate. This places Coloplast AS in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 17.90. Coloplast AS's value of 7.50% is 58.1% below this benchmark. While the company's 10-year median is 7.50 vs. the industry median of 17.90, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 17.90, based on 585 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current 3-Year FCF Growth Rate of 7.50% is 58.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 17.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current 3-Year FCF Growth Rate is 7.50%, which is near median its own 10-year median of 7.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.70 — trading 48.7% below its estimated fair value. The current 3-Year FCF Growth Rate is 7.50%, which is near median its 10-year median of 7.50 and 58.1% below the Medical Devices & Instruments industry median of 17.90. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current 3-Year FCF Growth Rate is 7.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.70 is trading 48.7% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
3-Year FCF Growth Rate: 7.50% (near median its 10-year median of 7.50)
GF Value™: $13.05 vs. price of $6.70 (48.7% below fair value)
Industry Position: 58.1% below the Medical Devices & Instruments median (#352 of 585)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
